Tower Cold Chain, CRYOPDP Collaborate on Growing Temperature-Controlled Offerings
The parties’ want to provide customers with a “one-stop-shop,” with the hopes that their services will be easier to navigate.
Tower Cold Chain and CRYOPDP are partnering up to boost their product offerings to the greater pharma supply chain.1 The agreement among the parties is expected to offer an array of solutions—mainly pertaining to clinical research—in order to address patient needs.
The companies are envisioning it as a “one-stop-shop” where customers can a peruse a variety of advanced temperature-controlled solutions and services, by providing access to company information (websites, booking services, etc.).
For one, Tower Cold Chain is utilizing CRYOPDP’s dry vapor shippers for cryogenic goods, which are capable of maintaining temperatures from -196°C to -150°C. Essentially, they consist of insulated aluminum vessels that are filled with liquid nitrogen and absorbent materials, in order to provide the proper transport and temperature preservation Overall, Tower’s passive temperature-controlled offerings all for it to accommodate temperature requirements from -196°C to +25°C.
As for CRYOPDP, the company will be providing customers with Tower’s KTEvolution range of fully reusable small boxes, available in 12-liter, 26-liter, and 57-liter options, which can support smaller payloads and last-mile delivery services at -80°C to +20°C temperature range.
“We are delighted to announce our collaboration with CRYOPDP, which allows us to expand our product range,” said Niall Balfour, Tower Cold Chain’s CEO. “This partnership enables Tower to offer sustainable, cryogenic-level solutions to the pharmaceutical supply chain, ultimately helping to improve patient outcomes worldwide.”
“Working with Tower Cold Chain enables us to become a one-stop shop for our customers,” commented Cedric Picaud, CEO of CRYOPDP. “We can now meet our sustainability targets by offering fully reusable containers for temperature-sensitive logistics. Together, we can provide pharmaceutical manufacturers with the most comprehensive range of temperature-controlled solutions available.”
Members of the industry who attended LogiPharma Europe earlier this year may recall the masterclass on “Unlocking the Benefits of Reusable Packaging: Enhancing Performance to Address Evolving Pharmaceutical Supply Chain and Patient Needs” that the parties led, featuring Martin Hawes, global head of product development, Tower Cold Chain, and Adri Sijben, senior business development director at CRYOPDP. The session explains the partnership’s effect on temperature-sensitive healthcare logistics, along with providing the benefits of reusable containers.
Being that reusability offers sustainable benefits for the environment, Hawes spoke with Pharma Commerce at LogiPharma Europe in which he described how companies in the industry can collaborate on these efforts.2
“I'm relatively new to the industry. I've been with Tower for three years, and one of the things that horrifies me is the amount of single-use packaging that the industry uses,” he noted. Well over 50% of all pallet shippers and small boxes are single use. That’s an inordinate amount of waste and a huge environmental impact. I’m hopeful that we can start persuading.
“Particularly now, people are more interested in the sustainability side of their business. So, our business is based on product life that exceeds well over five years, therefore much more circular solutions, and much better sustainability and low-waste opportunity. From a product development perspective, the challenge is building it now with robustness for no penalty of weight or volume, which we're starting to see now. I think as product values get higher, the potential of waste is much more significant."
References
1. Tower Cold Chain partners with CRYOPDP to expand temperature range. Tower Cold Chain. September 11, 2024. Accessed September 11, 2024. https://www.towercoldchain.com/tower-cold-chain-partners-with-cryopdp-to-expand-temperature-range/
2. Saraceno N. LogiPharma Europe 2024: Tower Cold Chain Global Head of Product Development Discusses the Future of Cell & Gene Therapy and Cold Chain Storage. Pharmaceutical Commerce. May 6, 2024. Accessed September 11, 2024. https://www.pharmaceuticalcommerce.com/view/logipharma-europe-2024-tower-cold-chain-global-head--product-development-discusses-the-future-of-cell-gene-therapy-and-cold-chain-storage
